Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Transneft will complete the expansion of oil pipelines to the Baltic and Kuban in 2024 and 2025

5/10/23 TRNFP

Nizhnekamskshina reported for 3 months of 2023 by RAS

5/10/23 NKSH

Herman Gref will continue to lead Sberbank

5/10/23 SBER

Polymetal intends to pay dividends before the separation of assets

5/10/23 POLY

Polymetal shareholders will consider the issue of redomiciliation in Kazakhstan on May 30

5/10/23 POLY

Polymetal in Q1 reduced production, but increased sales

5/10/23 POLY

Toyota reported for fiscal year 2023

5/10/23 7203

Airbnb reported 3 months of 2023

5/10/23 ABNB

Virgin Galactic reported for 3 months of 2023

5/10/23 SPCE

Electronic Arts reported for fiscal year 2023

5/10/23 EA